文献速递颈动脉与弓上血管

鱼精蛋白在经颈动脉血运重建中降低出血风险且不增加血栓栓塞事件

Protamine use in transcarotid artery revascularization is associated with lower risk of bleeding complications without higher risk of thromboembolic events.
PubMed 文献 · J Vasc Surg · 2020-04-06

基于VQI TCAR监测项目2016年9月至2019年4月的回顾性队列,5144例TCAR患者中4072例(79%)使用鱼精蛋白,倾向评分匹配944对后,鱼精蛋白组出血并发症风险显著降低(2.8% vs 8.3%;RR 0.33;95%CI 0.21-0.52;P<.001),院内卒中或死亡无显著差异,提示鱼精蛋白可安全用于TCAR以减少围术期出血。

要点

  • TCAR中使用鱼精蛋白与出血并发症风险降低相关(2.8% vs 8.3%;RR 0.33;95%CI 0.21-0.52;P<.001)。
  • 鱼精蛋白不增加院内卒中或死亡风险(1.6% vs 2.2%;RR 0.71;95%CI 0.37-1.39;P=.32)。
  • 鱼精蛋白组卒中风险有降低趋势但未达统计学显著(1.1% vs 2.0%;RR 0.53;95%CI 0.24-1.13;P=.09)。

核心结论

  • 鱼精蛋白可安全用于TCAR,降低围术期出血并发症风险而不增加血栓栓塞事件风险。

研究设计与样本

  • 回顾性综述VQI TCAR监测项目2016年9月至2019年4月行TCAR的患者,共5144例,其中4072例(79%)使用鱼精蛋白。
  • 采用倾向评分匹配944对使用与未使用鱼精蛋白的患者,评估院内结局。

主要发现

  • 鱼精蛋白组出血并发症发生率2.8%,未使用组8.3%(RR 0.33;95%CI 0.21-0.52;P<.001)。
  • 需介入治疗的出血发生率1.0% vs 3.6%(RR 0.26;95%CI 0.13-0.54;P<.001),需输血发生率1.2% vs 3.9%(RR 0.30;95%CI 0.15-0.58;P<.001)。
  • 院内卒中或死亡发生率1.6% vs 2.2%(RR 0.71;95%CI 0.37-1.39;P=.32),差异无统计学意义。
  • 卒中发生率1.1% vs 2.0%(RR 0.53;95%CI 0.24-1.13;P=.09),差异无统计学意义。
  • 短暂性脑缺血发作、心肌梗死、心力衰竭加重及术后低血压性血流动力学不稳定发生率均无显著差异。

关键数值与推荐

  • 主要疗效终点为穿刺点出血并发症,主要安全终点为院内卒中或死亡。
  • 出血并发症定义包括需介入治疗或需输血的出血事件。

临床怎么用

  • 在TCAR围术期可考虑使用鱼精蛋白中和肝素,以降低穿刺点出血及相关干预风险。
  • 使用鱼精蛋白不增加卒中、死亡等血栓栓塞事件风险,可安全应用于TCAR患者。

局限性

  • 回顾性研究设计,存在选择偏倚可能,虽经倾向评分匹配但无法排除未测量混杂因素。
  • 仅评估院内结局,缺乏长期随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Recent studies have found that transcarotid artery revascularization (TCAR) is associated with lower risk of stroke or death compared with transfemoral carotid artery stenting but higher risk of bleeding complications, presumably associated with the need for an incision. Heparin anticoagulation is universally used during TCAR, so protamine use may reduce bleeding complications. However, the safety and effectiveness of protamine use in TCAR are unknown. We therefore evaluated the impact of protamine use on perioperative outcomes after TCAR in the Vascular Quality Initiative TCAR Surveillance Project. METHODS: We performed a retrospective review of patients undergoing TCAR in the Vascular Quality Initiative TCAR Surveillance Project from September 2016 to April 2019. We assessed in-hospital outcomes using propensity score-matched cohorts of patients who did and did not receive protamine. The primary efficacy end point was access site bleeding complications, and the primary safety end point was in-hospital stroke or death. Secondary end points included the individual end points of stroke, death, transient ischemic attack, myocardial infarction, congestive heart failure exacerbation, and hemodynamic instability. RESULTS: Of the 5144 patients undergoing TCAR, all patients received heparin and 4072 (79%) patients received protamine. We identified 944 matched pairs of patients who did and did not receive protamine. Protamine use was associated with a significantly lower risk of bleeding complications (2.8% vs 8.3%; relative risk [RR], 0.33; 95% confidence interval [CI], 0.21-0.52; P < .001), including bleeding that resulted in interventional treatment (1.0% vs 3.6%; RR, 0.26; 95% CI, 0.13-0.54; P < .001) and in blood transfusion (1.2% vs 3.9%; RR, 0.30; 95% CI, 0.15-0.58; P <.001). There were no statistically significant differences in in-hospital stroke or death for patients who received protamine and those who did not (1.6% vs 2.2%; RR, 0.71; 95% CI, 0.37-1.39; P = .32); however, there was a trend toward lower risk of stroke for patients who received protamine (1.1% vs 2.0%; RR, 0.53; 95% CI, 0.24-1.13; P = .09). There were also no statistically significant differences in the rates of transient ischemic attack (0.4% vs 1.1%; RR, 0.40; 95% CI, 0.13-1.28; P = .11), myocardial infarction (0.4% vs 0.8%; RR, 0.50; 95% CI, 0.15-1.66; P = .25), heart failure exacerbation (0.4% vs 0.3%; RR, 1.33; 95% CI, 0.30-5.96; P = .71), or postoperative hypotensive hemodynamic instability (16% vs 15%; RR, 1.06; 95% CI, 0.83-1.35; P = .50) with protamine use. CONCLUSIONS: Protamine can be safely used in TCAR to reduce the risk of perioperative bleeding complications without increasing the risk of thrombotic events.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Liang P, Motaganahalli RL, Malas MB, et al. Protamine use in transcarotid artery revascularization is associated with lower risk of bleeding complications without higher risk of thromboembolic events. J Vasc Surg. 2020. PMID: 32273225. doi:10.1016/j.jvs.2020.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。